Indee Labs in enabling T cell immunotherapy manufacturing. The team is developing a simple, scalable system based on microfluidic vortex shedding (µVS) to rapidly deliver nucleic acids, proteins, and complexes to T cells with high yield and minimal perturbation of the T cell state.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
µVS Delivery System
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):